Niacin (B3) for Non-melanoma skin cancer (nicotinamide) and Niacin (B3)
Each entry’s own grades, side by side. A grade says how strong the evidence is for one outcome — it does not rank one entry over the other.
Evidence brief
Niacin (B3) for Non-melanoma skin cancer (nicotinamide)
Evidence grade B — In high-risk patients
Grade B1 graded outcomerevised Jul 10, 2026
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
Compound or practice
Niacin (B3)
Corrects pellagra, powerfully shifts blood lipids — but as a heart drug it failed to cut events and added harm.
Grade B4 graded outcomesrevised Jul 10, 2026
A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.
Graded in both
Outcomes are matched by name. Two entries can describe the same outcome in different words, so one listed further down may still be graded in the other.
| Outcome | Niacin (B3) for Non-melanoma skin cancer (nicotinamide) | Niacin (B3) |
|---|---|---|
| Non-melanoma skin cancer (nicotinamide) | Evidence grade BSmall effectmixedIn high-risk patients | Evidence grade BSmall effectmixedIn high-risk patients |
Graded only in Niacin (B3) for Non-melanoma skin cancer (nicotinamide)
None — every outcome it grades is graded in both.
Graded only in Niacin (B3)
- Pellagra Large effectEvidence grade A
- HDL / triglycerides Large effectEvidence grade A
- Cardiovascular events Trivial effectEvidence grade D
What each entry says about the other
- Niacin (B3) for Non-melanoma skin cancer (nicotinamide)’s entry · Goes with: Read the full Niacin (B3) monograph
Both columns are read from the entries as they stand in this library. A comparison is not advice to take either one, and it is no substitute for a clinician who knows the person.